p53与消化系统恶性肿瘤的研究进展

doi:10.11904/j.issn.1002-3070.2016.05.017

Abstract

Abstract: p53,the widely studied tumor suppressor gene,plays a key role in regulating cell cycle,repairing DNA damages,eliminating free radicals and regulating immune responses and so on.The recent studies showed that p53 mutation was in close biological connections with the occurrence,development,infiltration and metastasis in over 50 percent digestive systemic malignant tumors.In view of the current researches,we review the biological features of p53,the relationship between p53 and digestive systemic malignant tumors,and gene therapy of p53 to provide references for the pathogenesis,diagnosis,treatment and prognosis of digestive systemic malignant tumors in this paper.

Key words: p53, Mutation, Digestive systemic malignant tumors, Gene therapy

CLC Number:

R73.5

WANG Peng, WANG Zheng, ZHOU Zhixiang. Roles of p53 in the interaction with digestive malignant tumors[J]. PRACTICAL ONCOLOGY JOURNAL, 2016, 30(5): 468-472.

References

1 Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
2 Li T,Kon N,Jiang L,et al.Tumor suppression in the absence of p53-mediated cell-cycle arrest,apoptosis,and senescence[J].Cell,2012,149(6):1269-1283.
3 苏明慧,王大成.p53基因的研究进展[J].内蒙古医学杂志,2011,43(19):46-49.
4 Momand J,Wu HH,Dasgupta G.MDM2—master regulator of the p53 tumor suppressor protein[J].Gene,2000,242(1/2):15-29.
5 Grossman SR,Deato ME,Brignone C,et al.Polyubiquitination of p53 by a ubiquitin ligase activity of p300[J].Science,2003,300(5617):342-344.
6 Takagi M,Absalon MJ,Mclure KG,et al.Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin[J].Cell,2005,123(1):49-63.
7 Karim S,Ali A.Correlation of p53 over-expression and alteration in p53 gene detected by polymerase chain reaction-single strand conformation polymorphism in adenocarcinoma of gastric cancer patients from India[J].World J Gastroenterol,2009,15(11):1381-1387.
8 Song H,Hollstein M,Xu Y.p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM[J].Nat Cell Biol,2007,9(5):573-580.
9 Wei W,Wang Y,Yu X,et al.Expression of TP53,BCL-2,and VEGFA genes in esophagus carcinoma and its biological significance[J].Med Sci Monit,2015,21(3):3016-3022.
10 Yao W,Qin X,Qi B,et al.Association of p53 expression with prognosis in patients with esophageal squamous cell carcinoma[J].Int J Clin Exp Pathol,2014,7(10):7158-7163.
11 Li S,Li J,Liu Z,et al.Predictive value of P53,Ki-67,HER2 protein detection in neoadjuvant chemotherapy for adenocarcinoma of gastroesophageal junction[J].Zhonghua Wei Chang Wai Ke Za Zhi,2015,18(9):901-904.
12 Busuttil RA,Zapparoli GV,Haupt S,et al.Role of p53 in the progression of gastric cancer[J].Oncotarget,2014,5(23):12016-12026.
13 Wei K,Jiang L,Wei Y,et al.The prognostic significance of p53 expression in gastric cancer:a meta-analysis[J].J Cancer Res Clin Oncol,2015,141(4):735-748.
14 Babacan NA,Egilmez HR,Yucel B,et al.The prognostic value of UHRF-1 and p53 in gastric cancer[J].Saudi J Gastroenterol,2016,22(1):25-29.
15 Calik M,Demirci E,Altun E,et al.Clinicopathological importance of Ki-67,p27,and p53 expression in gastric cancer[J].Turk J Med Sci,2015,45(1):118-128.
16 Yan WF,Wu G,Sun PC,et al.P53 mutations occur more commonly than KRAS mutations in colorectal adenoma[J].Int J Clin Exp Med,2015,8(1):1370-1375.
17 Horvath B,Liu G,Wu X,et al.Overexpression of p53 predicts colorectal neoplasia risk in patients with inflammatory bowel disease and mucosa changes indefinite for dysplasia[J].Gastroenterol Rep(Oxf),2015,3(4):344-349.
18 Cooks T,Pateras IS,Tarcic O,et al.Mutant p53 prolongs NF-kappaB activation and promotes chronic inflammation and inflammation-associated colorectal cancer[J].Cancer Cell,2013,23(5):634-646.
19 Iwamuro M,Kawai Y,Matsumoto T,et al.Serum anti-p53 antibody as a tumour marker for colorectal cancer screening[J].Ecancermedicalscience,2015,9(3):560-571.
20 Dong C,Zhao B,Long F,et al.Nogo-B receptor promotes the chemoresistance of human hepatocellular carcinoma via the ubiquitination of p53 protein[J].Oncotarget,2016,7(8):8850-8865.
21 Chen J,Wang H,Wang J,et al.STAT1 inhibits human hepatocellular carcinoma cell growth through induction of p53 and Fbxw7[J].Cancer Cell Int,2015,15:111.
22 Gomes AR,Abrantes AM,Brito AF,et al.Influence of P53 on the radiotherapy response of hepatocellular carcinoma[J].Clin Mol Hepatol,2015,21(3):257-267.
23 Ghosh M,Sakhuja P,Singh S,et al.p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer[J].Saudi J Gastroenterol,2013,19(1):34-39.
24 Cai W,Li Q,Yang Z,et al.Expression of p53 upregulated modulator of apoptosis(PUMA)and C-myb in gallbladder adenocarcinoma and their pathological significance[J].Clin Transl Oncol,2013,15(10):818-824.
25 Kim K,Kim DH,Chae SW,et al.Expression of cell cycle-related proteins,p16,p53 and p63 as important prognostic markers in gallbladder adenocarcinoma[J].Pathol Oncol Res,2014,20(2):409-415.
26 Kim H,Park CY,Lee JH,et al.Ki-67 and p53 expression as a predictive marker for early postoperative recurrence in pancreatic head cancer[J].Ann Surg Treat Res,2015,88(4):200-207.
27 Kurahara H,Maemura K,Mataki Y,et al.Impact of p53 and PDGFR-beta expression on metastasis and prognosis of patients with pancreatic cancer[J].World J Surg,2016,40(8):1977-1984.
28 Xiang JF,Wang WQ,Liu L,et al.Mutant p53 determines pancreatic cancer poor prognosis to pancreatectomy through upregulation of cavin-1 in patients with preoperative serum CA19-9≥1,000 U/mL[J].Sci Rep,2016,6:19222.
29 Guan YS,Liu Y,He Q,et al.p53 gene therapy in combination with transcatheter arterial chemoembolization for HCC:one-year follow-up[J].World J Gastroenterol,2011,17(16):2143-2149.
30 Yang ZX,Wang D,Wang G,et al.Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma[J].J Cancer Res Clin Oncol,2010,136(4):625-630.

[1]	SHI Jun, NI Xiaobing, MAO Min, PENG Xingchun. Inhibitory effect and mechanism of Nultin-3 combined with cisplatin on oral squamous cell carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(6): 488-492.
[2]	HE Wei, MU Qiming, WANG Gang, WAN Bo, LIAO Bo, YANG Juan. Expression of TACC3 and p53 protein in primary liver cancer and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(5): 420-425.
[3]	LIANG Guanying,CHI Qiujun,LI Xiaomei. Effect and mechanism of Vorinostat on the proliferation and apoptosis of ovarian cancer SKOV3 cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(4): 298-302.
[4]	YAN Shi, HUO Mingming, PANG Hui, LI Yan, CAI Li. Effects of p53 on predictive value for efficacy of endocrine drugs in postoperative postmenopausal breast cancer patients with HR positive and HER-2 positive [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 234-213.
[5]	ZHANG Ting, JIA Di, YANG Dan. Progress in biological treatment of osteosarcoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2018, 32(3): 254-257.
[6]	CHEN Zhuo, KONG Yiran. Effect of silencing UHRF1 on proliferation and metastasis of breast cancer cells [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 512-518.
[7]	WANG Zhiguo, WU Xiaodan, ZHAN Ying, ZHANG Tong, ZHANG Guoxu. The correlation between glucose metabolism and BRAF mutation in ¹⁸F-FDG PET/CT imaging of papillary thyroid carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2017, 31(6): 519-523.
[8]	XING Qi,ZHANG Qian,QIAO Wenbo. Research advances on cytokines and prevention in radiation induced lung injury [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(3): 250-253.
[9]	XU Yanbin,LI Jianhua. General situation of radioactive particles therapy and gene therapy in gliomas [J]. PRACTICAL ONCOLOGY JOURNAL, 2015, 29(2): 153-156.
[10]	LIU Bingmei,YANG Jing,ZHANG Hanwen,XING Ronggui,LI Lili,ZHAO Liping,QIAO Shi,YOU Haiyan. The research on expression of cell cycle and apoptosis related protein in keratoacanthoma and well-differentiated squamous cell carcinoma [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 485-491.
[11]	XU Ruirui,WEN Liyuan,SUN Guoqiang,MENG Qingwei,SUN Lichun,CAI Li. Research on the expression of Caveolin-1 with EGFR mutations in non-small cell lung cancer tissues and its clinical significance [J]. PRACTICAL ONCOLOGY JOURNAL, 2014, 28(6): 498-502.
[12]	XIAO Qin,GU Xuewen,TIAN Xiuchun,WANG Cuimei. Expression and its clinical significance of p53 and Epidermal growth factor receptor(EGFR)in gastric cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(6): 532-539.
[13]	CHENG Wen,SHAO Hua,LI Jiebing,YANG Xian,ZHANG Guoqiang,SHEN Baozhong,GENG Jingshu. Basic study on targeted therapy of liver cancer using human wild-type p53 plasmid by ultrasound with ultrasonic contrast agents [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 298-301.
[14]	SU Jun,ZHANG Xuexin,CHANG Liang,ZHANG Rui,JIN Hua,ZHANG Lei,WANG Hongbin. The changes and significance of p53 and MDM2 expression in the patients with recurrent and malignant development of low grade glioma [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 311-313.
[15]	LI Na,HONG Xuan,CHEN Gongyan. Progress of c-kit in small cell lung cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2012, 26(4): 381-384.

Roles of p53 in the interaction with digestive malignant tumors

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments